Dr. Chris Skedgel, MDE, PhD
Research Health Economist, Atlantic Clinical Cancer Research Unit, Capital Health; Adjunct Appointment, Department of Medicine, Dalhousie University & Capital Health
Capital Health, Dalhousie University
Health economic evaluation, decision modelling, societal preferences, conjoint analysis.
Maximizing the value of heathcare
Chris splits his time between the Maritime Strategy for Patient-Oriented Research (SPOR) Support Unit (MSSU), and the Atlantic Clinical Cancer Research Unit (ACCRU). His interest is in the use of heath economics to maximize the value of limited healthcare resources, including consideration of economic efficiency as well as the broader concepts of public preferences and societal value. In considering these different conceptions of value, he uses tools such as economic modeling and stated preference elicitation.
Membership Status:Mr. Skedgel is a BHCRI Associate Member.
Address:Centre for Clinical Research, 5790 University Ave, Halifax, NS B3H 1V7
Skedgel C, Rayson D, Younis T. Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? Annals of Oncology [In Press, Feb 2013]
Lamond NWD, Skedgel C, Rayson D, Lethbridge L, Younis T. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Research & Treatment. 2012; 133(3): 1115-1123.
Younis T, Skedgel C. Adjuvant Trastuzumab for Breast Cancer: Uncertainties in Clinical and Economic Evidence Following Early Stopping of the HERA Trial. Pharmacoeconomics. 2011; 29(5): 361-65.
Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with HER2/neu-positive breast cancer: an analysis based on the updated HERA trial results. Value in Health. 2009; 12(5): 641-648.
Younis T, Rayson D, Sellon M, Skedgel C. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Research & Treatment. 2008; 111(2): 261-267.
Drucker A, Skedgel C, Virik K, Rayson D, Sellon M, Younis T. The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada. Medical Oncology. 2008; 15(3): 136-142.
Younis T, Skedgel C. Is trastuzumab a cost-effective treatment for breast cancer? Expert Review of Pharmacoeconomics & Outcomes Research. 2008; 8(5): 433-442.
Skedgel C, Rayson D, Dewar R, Younis T. Cost-Utility of Adjuvant Hormone Therapies with Aromatase Inhibitors in Post-Menopausal Women with Breast Cancer: Upfront Anastrozole, Sequential Tamoxifen-Exemestane and Extended Tamoxifen-Letrozole. The Breast. 2007: 16; 252-261.
Younis T, Rayson D, Dewar R, Skedgel C. Modeling for Cost-Effective Adjuvant Aromatase Inhibitor Strategies for Postmenopausal Women with Breast Cancer. Annals of Oncology. 2007; 18(2): 293-298.
Skedgel C, Rayson D, Dewar R, Younis T. Cost-Utility of Adjuvant Hormone Therapies for Breast Cancer in Post-Menopausal Women: Sequential Tamoxifen-Exemestane and Upfront Anastrozole. Breast Cancer Research & Treatment. 2007; 101(3): 325-333.